Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board  >  Regen BioPharma Inc    

REGEN BIOPHARMA INC

My previous session
Most popular
SummaryChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/12/2018 | 12:38pm EST

Item 5.03 Amendments to Articles of Incorporation

On October 11, 2018Regen Biopharma, Inc. amended its Certificate of Incorporation increasing its authorized common shares from 500,000,000 with a par value of 0.0001 to 800,000,000 with a par value of 0.0001

2

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGEN BIOPHARMA INC
02/12REGEN BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
01/25REGEN BIOPHARMA INC : Change in Directors or Principal Officers (form 8-K)
AQ
01/11REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
2018ENTEST GROUP, INC. : Changes in Control or Registrant, Change in Directors or Pr..
AQ
2018ENTEST : Management's Discussion and Analysis of Financial Condition and Results..
AQ
2018REGEN BIOPHARMA INC : Entry into a Material Definitive Agreement, Termination of..
AQ
2018ENTEST GROUP, INC. : Entry into a Material Definitive Agreement, Termination of ..
AQ
2018REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
2018REGEN BIOPHARMA INC : Regulation FD Disclosure, Other Events (form 8-K)
AQ
2018REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities (form 8-K)
AQ
More news
Chart REGEN BIOPHARMA INC
Duration : Period :
Regen BioPharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
David Raymond Koos Chairman, CEO, Secretary & Treasurer
Todd S. Caven Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
REGEN BIOPHARMA INC-48.32%0
GILEAD SCIENCES5.42%85 858
VERTEX PHARMACEUTICALS11.79%47 462
REGENERON PHARMACEUTICALS9.37%44 554
GENMAB-5.76%9 362
SAREPTA THERAPEUTICS INC23.60%9 013